Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Atezolizumab
Indication/Tumor Type lung non-small cell carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab Guideline Actionable Tecentriq (atezolizumab) is included in guidelines as adjuvant therapy for non-small cell lung cancer patients with PD-L1 expression >/= 1% and negative for EGFR exon 19 deletion, L858R, or ALK rearrangements who have received prior adjuvant chemotherapy (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (IMpower010) that supported FDA approval, adjuvant Tecentriq (atezolizumab) treatment following resection and chemotherapy improved disease-free survival compared to best supportive care (HR 0·66, p=0·0039) in patients with stage II-IIIA non-small cell lung cancer whose tumors expressed CD274 (PD-L1) on 1% or more of tumor cells (PMID: 34555333; NCT02486718). detail... 34555333 detail...
PubMed Id Reference Title Details
NCCN.org Full reference...
Full reference...
Tecentriq (atezolizumab) FDA Drug Label Full reference...
(34555333) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Full reference...